A Phase 3 interventional study of human immunoglobulin G and Placebo in Dermatomyositis, sponsored by CSL Behring. Terminated at 76 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies in Dermatomyositis with a site in United States — 30 open to participants now, 33 under way, 6 of them phase 3. Dermatomyositis · United States.
Among the 94 studies in Dermatomyositis with a site in United States, this one is the 15th largest by enrollment of the 73 interventional ones that give a count, is one of 3 that started in 2019, is one of 9 in phase 3, and was the 52nd registered.
184 studies on the registry are indexed under Dermatomyositis; 63 are open to participants now.
Browse Dermatomyositis studies →30 of the 94 studies in Dermatomyositis with a site in United States are open now. Recruiting first, the newest first:
National Institute of Environmental Health Sciences (NIEHS) · Sites in United States
Ages 18–62
Fate Therapeutics · Sites in United States
Ages 18–70
University of Miami · Sites in United States
Ages 18+
Cartesian Therapeutics · Sites in United States
Ages 12+
Restem, LLC. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 50 Dermatomyositis studies recruiting now, 24 (48%) set no upper age limit and 16 (32%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 42 · Phase 3 17 · Phase 4 2
First in 1990; this study’s year is marked. 3 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 134 is above the median of 35 across 130 interventional studies indexed under Dermatomyositis.
Median enrollment 25 across the 73 interventional studies, 540 across the 18 observational. Of the 55 that completed or were terminated, 26 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 94 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
CSL Limited has 1 study filed under Dermatomyositis — fewer than ten, so there is no comparison to draw.
5 of the studies in Dermatomyositis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06284954argenxA Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | 2026-11 |
| NCT06371417Chugai PharmaceuticalPhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial) | 2027-03-31 |
| NCT06298019Stanford UniversityStudy of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis | 2027-04 |
| NCT06916806AstraZenecaA Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. | 2027-05-05 |
| NCT07486869University of MiamiEmapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study | 2027-07 |
Add all 5 to your calendar (.ics) → With an account.
Among the 94 studies in Dermatomyositis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of IgPro20 (subcutaneous Ig) treatment in adult subjects with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of IgPro20 subcutaneous (SC) doses in comparison to placebo in adult subjects with DM, as measured by responder status based on Total Improvement Score (TIS) assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
human immunoglobulin G administered subcutaneously
Drug: human immunoglobulin G
human albumin solution administered subcutaneously
Drug: Placebo
human immunoglobulin G administered subcutaneously
Also known as: IgPro20, Hizentra
contains 2% human albumin, similar excipients as IgPro20 (Hizentra), same volume, same duration, administered subcutaneously
Responder Rate
A responder was defined as a participant with a TIS \>= 20 points at Week 25 and at least 1 of the previous scheduled visits (Week 17 or 21), who completes 24 weeks of randomized IMP treatment without the use of rescue corticosteroid treatment. The TIS was a sum response criterion which incorporates 6 weighted international myositis assessment and clinical studies (IMACS) core set measures (CSMs) including Physician and Patient Global Disease Activity (PGA), Manual Muscle Testing-8 (MMT-8), Health Assessment Questionnaire, Muscle Enzyme, and Extramuscular Global Activity (EGA). Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points, respectively on the TIS. Percentage of responders at Week 25 based on TIS are reported here. Multiple imputation (MI) was used to impute missing values for participants who discontinued due to the military activities in Ukraine.
Time frame: At Week 25
Mean TIS
The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100; higher the score, better the condition), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points, respectively on the TIS. Least squares (LS) means were estimated using a mixed model repeated measures (MMRM) including treatment, visit, the interaction between treatment and visit, region, and baseline MMT-8 (\<=142 points vs \>142 points) as fixed effects, participant as a random effect.
Time frame: At Week 25
Mean Changes From Baseline in MMT-8
The MMT-8 was a set of 8 designated muscles which were tested bilaterally (potential score ranging from 0 to 150): 7 biaxial muscles with a potential score 0 to 140 and 1 axial (neck flexors) with a potential score of 0 to 10. Improvement is documented with an increase in score. LS means were estimated using a MMRM including treatment, visit, the interaction between treatment and visit, and region as fixed effects, baseline MMT-8 as a continuous covariate and participant as a random effect.
Time frame: From Baseline to Week 25
Mean Changes From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index Total Activity Score (CDASI-A)
The CDASI in its modified version 2 (V2) is a validated tool of skin disease activity (3 items) and damage (3 items) assessment. Scores range from 0-100 for activity and from 0-32 for damage. Improvement is documented with a decrease in score. LS means were estimated using a MMRM including treatment, visit, the interaction between treatment and visit, region, and baseline MMT-8 (\<=142 points vs \>142 points) as fixed effects, baseline CDASI-A as a continuous covariate, and participants as a random effect.
Time frame: From Baseline to Week 25
Percentage of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%
Reduction in corticosteroid dose.
Time frame: At Week 25
Period 1: Mean TIS at Each Visit
The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points on the TIS.
Time frame: At Week 5, 9, 13, 17, 21, and 25
Period 2: Mean TIS at Each Visit
The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points on the TIS.
Time frame: Week 25, 29, 33, 37, 41, 45, 49, and 53
Period 1: Percentage of Participants Achieving TIS ≥ 20, ≥ 40 and ≥ 60 Points
Participants were considered and reported in more than one category (TIS \>= 20, \>= 40 and \>= 60 Points).
Time frame: At Week 5, 9, 13, 17, 21, and 25
Period 2: Percentage of Participants Achieving TIS ≥ 20, ≥ 40 and ≥ 60 Points
Participants were considered and reported in more than one category (TIS \>= 20, \>= 40 and \>= 60 Points).
Time frame: Week 25, 29, 33, 37, 41, 45, 49, and 53
Period 1: Time to First Achieving TIS >= 20, >= 40, and >= 60 Points on the TIS
The observation was censored if no improvement was observed before the intake of rescue/increased doses of oral corticosteroids in SP1 or before the end of the period.
Time frame: Up to Week 25
Period 1 and 2: Time to First Achieving TIS >= 20, >= 40, and >= 60 Points Improvement on the TIS
The observation was censored if no improvement was observed before the intake of rescue/increased doses of oral corticosteroids in SP1 or before the end of the period.
Time frame: Up to Week 53
Mean Changes From Baseline in Individual CSMs (Except Muscle Enzymes) and CDASI
Individual CSMs included following: Myositis Disease Activity Assessment Tool (MDAAT) Physician global disease activity (PGDA), PGA assessment, MMT-8, health assessment questionnaire-disability index (HAQ-DI), and MDAAT-EGA. Higher values were associated with a better state of health for the MMT-8 (range 0 -150) assessment, while lower values were associated with a better state of health for: MDAAT-PGDA (range 0 -100), PGA (range 0-100), HAQ-DI (range 0-3), MDAAT-EGA (range 0 -100), and CDASI-A (range 0-100).
Time frame: From Baseline to Week 25
Mean Changes From Week 25 in Individual CSMs (Except Muscle Enzymes) and CDASI
Individual CSMs included following: MDAAT-PGDA, PGA assessment, MMT-8, HAQ-DI, and MDAAT extramacular global assessment. Higher values were associated with a better state of health for the MMT-8 (range 0 -150) assessment, while lower values were associated with a better state of health for: MDAAT-PGDA (range 0 -100), PGA (range 0-100), HAQ-DI (range 0-3), MDAAT-EGA (range 0 -100), and CDASI-A (range 0-100).
Time frame: From Week 25 to Week 53
Period 1: Number of Participants Meeting Definition of Worsening (DOW) at Least Once, Twice, or > Twice
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment Visual Analog Scale (VAS) worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)
Time frame: Up to Week 25
Period 1: Percentage of Participants Meeting DOW at Least Once, Twice, or > Twice
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)
Time frame: Up to Week 25
Period 2: Number of Participants Meeting DOW at Least Once, Twice, or > Twice
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)
Time frame: From Week 25 up to Week 53
Period 2: Percentage of Participants Meeting DOW at Least Once, Twice, or > Twice
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)
Time frame: From Week 25 up to Week 53
Time to Meeting DOW for the First Time
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The observation was censored if no DOW was observed before the intake of rescue treatment or before the end of the period.
Time frame: Up to Week 53
Number of Participants Meeting DOW and Receiving Rescue Steroid Treatment
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The Number of participants meeting DOW and who received rescue steroid treatment are reported here.
Time frame: Up to Week 25
Percentage of Participants Meeting DOW and Receiving Rescue Steroid Treatment
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The percentage of participants meeting DOW and who received rescue steroid treatment are reported here.
Time frame: Up to Week 25
Number of Participants Who Start Oral Corticosteroid Dose Taper
Time frame: Up to Week 25
Percentage of Participants Who Start Oral Corticosteroid Dose Taper
Time frame: Up to Week 25
Number of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%, >= 50%, >= 75%
Time frame: Up to Week 25 and 52
Percentage of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25%, >= 50%, >= 75%
Time frame: Up to Week 25 and 52
Percentage of Participants Receiving Rescue Corticosteroid Treatment
Time frame: Up to Week 25
Percentage of Participants Whose Rescue Corticosteroid Treatment is Tapered
Time frame: Up to Week 25
Time to First Intake of Rescue Corticosteroid Treatment
The observation was censored if no Rescue was observed before the last day of the last week with IMP intake or before the end of the period.
Time frame: Up to Week 25
Number of Participants Having at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Baseline in Mobility, Self-care, and Usual Activities Domains of EuroQoL 5-Dimension Questionnaire (EQ-5D-5L)
EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.
Time frame: From Baseline to Week 13 and 25
Percentage of Participants Having at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L
EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.
Time frame: From Baseline to Week 13 and 25
Number of Participants Having no Reduction in Levels, at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Week 25 in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L
EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having no reduction, at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.
Time frame: From Week 25 to 41 and 53
Percentage of Participants Having no Reduction in Levels, at Least 1 Level, 2 Levels, and More Than 2 Levels of Improvement From Week 25 in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L
EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having no reduction, at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.
Time frame: From Week 25 to 41 and 53
Percentage of Participants With Treatment Emergent Adverse Events (TEAEs), Related TEAEs and Serious TEAEs
Time frame: Up to 5 years
Annualized Rate of TEAEs, Related TEAEs and Serious TEAEs Per Time at Risk
Time frame: Up to 5 years
Annualized Rate of Mild, Moderate, and Severe TEAEs Per Time at Risk
Time frame: Up to 5 years
This study was conducted from 21 October 2019 to 02 December 2024.
| Milestone | Sequence A: IgPro20 / IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 / IgPro20 |
|---|---|---|
| Started | 67 | 67 |
| Treated | 67 | 67 |
| Completed | 56 | 55 |
| Not completed | 11 | 12 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 5 |
| Withdrew: Protocol deviation | 2 | 0 |
| Withdrew: Site terminated by sponsor | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 1 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Other: unspecified | 1 | 0 |
| Milestone | Sequence A: IgPro20 / IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 / IgPro20 |
|---|---|---|
| Started | 56 | 55 |
| Treated | 56 | 55 |
| Completed | 40 | 38 |
| Not completed | 16 | 17 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Withdrawal by subject | 5 | 5 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Site terminated by sponsor | 1 | 3 |
| Withdrew: Study terminated by sponsor | 8 | 3 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Other: unspecified | 1 | 1 |
| Milestone | Sequence A: IgPro20 / IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 / IgPro20 |
|---|---|---|
| Started | 36 | 34 |
| Treated | 36 | 34 |
| Completed | 11 | 12 |
| Not completed | 25 | 22 |
| Withdrew: Site terminated by sponsor | 1 | 2 |
| Withdrew: Study terminated by sponsor | 24 | 18 |
| Withdrew: Missing | 0 | 2 |
A responder was defined as a participant with a TIS \>= 20 points at Week 25 and at least 1 of the previous scheduled visits (Week 17 or 21), who completes 24 weeks of randomized IMP treatment without the use of rescue corticosteroid treatment. The TIS was a sum response criterion which incorporates 6 weighted international myositis assessment and clinical studies (IMACS) core set measures (CSMs) including Physician and Patient Global Disease Activity (PGA), Manual Muscle Testing-8 (MMT-8), Health Assessment Questionnaire, Muscle Enzyme, and Extramuscular Global Activity (EGA). Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points, respectively on the TIS. Percentage of responders at Week 25 based on TIS are reported here. Multiple imputation (MI) was used to impute missing values for participants who discontinued due to the military activities in Ukraine.
| percentage of participants | IgPro20 | Placebo |
|---|---|---|
| Responder Rate | 64.3 (52.56 to 75.99) | 61.6 (49.52 to 73.74) |
The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100; higher the score, better the condition), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points, respectively on the TIS. Least squares (LS) means were estimated using a mixed model repeated measures (MMRM) including treatment, visit, the interaction between treatment and visit, region, and baseline MMT-8 (\<=142 points vs \>142 points) as fixed effects, participant as a random effect.
| score on a scale | IgPro20 | Placebo |
|---|---|---|
| Mean TIS | 32.24 (25.275 to 39.208) | 30.78 (23.668 to 37.896) |
The MMT-8 was a set of 8 designated muscles which were tested bilaterally (potential score ranging from 0 to 150): 7 biaxial muscles with a potential score 0 to 140 and 1 axial (neck flexors) with a potential score of 0 to 10. Improvement is documented with an increase in score. LS means were estimated using a MMRM including treatment, visit, the interaction between treatment and visit, and region as fixed effects, baseline MMT-8 as a continuous covariate and participant as a random effect.
| score on a scale | IgPro20 | Placebo |
|---|---|---|
| Mean Changes From Baseline in MMT-8 | 8.9 (4.08 to 13.78) | 11.3 (4.79 to 17.89) |
The CDASI in its modified version 2 (V2) is a validated tool of skin disease activity (3 items) and damage (3 items) assessment. Scores range from 0-100 for activity and from 0-32 for damage. Improvement is documented with a decrease in score. LS means were estimated using a MMRM including treatment, visit, the interaction between treatment and visit, region, and baseline MMT-8 (\<=142 points vs \>142 points) as fixed effects, baseline CDASI-A as a continuous covariate, and participants as a random effect.
| score on a scale | IgPro20 | Placebo |
|---|---|---|
| Mean Changes From Baseline in Cutaneous Dermatomyositis Disease Area and Severity Index Total Activity Score (CDASI-A) | -10.6 (-13.28 to -7.82) | -5.3 (-8.29 to -2.28) |
Reduction in corticosteroid dose.
| percentage of participants | IgPro20 | Placebo |
|---|---|---|
| Percentage of Participants Who Are Able to Reduce the Oral Corticosteroid Dose by >= 25% | 23.2 (12.89 to 33.45) | 20.2 (10.39 to 30.04) |
The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points on the TIS.
| score on a scale | IgPro20 | Placebo |
|---|---|---|
| Week 5 | 23.22 ± 16.387 | 20.97 ± 16.684 |
| Week 9 | 32.54 ± 18.132 | 26.67 ± 17.924 |
| Week 13 | 37.68 ± 17.267 | 31.68 ± 20.705 |
| Week 17 | 41.00 ± 16.926 | 35.44 ± 21.458 |
| Week 21 | 43.56 ± 17.112 | 36.67 ± 21.882 |
| Week 25 | 40.20 ± 20.093 | 40.21 ± 21.812 |
The TIS was a sum response criterion which incorporates 6 weighted IMACS CSMs including Physician and PGA, MMT-8, Health Assessment Questionnaire, Muscle Enzyme, and EGA. A total improvement score (range 0 to 100), determined by summing scores for each CSM, was based on improvement in and relative weight of each CSM. Thresholds for minimal, moderate, and major improvement were \>= 20, \>= 40, and \>= 60 points on the TIS.
| score on a scale | Sequence A: IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 |
|---|---|---|
| Week 25 | 40.09 ± 19.547 | 38.08 ± 22.658 |
| Week 29 | 45.05 ± 19.931 | 42.74 ± 20.057 |
| Week 33 | 44.66 ± 19.346 | 46.23 ± 18.258 |
| Week 37 | 47.81 ± 18.805 | 48.49 ± 17.071 |
| Week 41 | 50.49 ± 18.255 | 51.68 ± 15.943 |
| Week 45 | 50.89 ± 19.018 | 52.94 ± 15.078 |
| Week 49 | 51.63 ± 17.844 | 50.51 ± 16.010 |
| Week 53 | 50.32 ± 15.886 | 54.26 ± 15.022 |
Participants were considered and reported in more than one category (TIS \>= 20, \>= 40 and \>= 60 Points).
| percentage of participants | IgPro20 | Placebo |
|---|---|---|
| Week 5: TIS >= 20 Points | 47.7 (35.15 to 60.46) | 47.7 (35.15 to 60.46) |
| Week 5: TIS >= 40 Points | 16.9 (8.76 to 28.27) | 15.4 (7.63 to 26.48) |
| Week 5: TIS >= 60 Points | 1.5 (0.04 to 8.28) | 1.5 (0.04 to 8.28) |
| Week 9: TIS >= 20 Points | 63.1 (50.20 to 74.72) | 56.3 (43.28 to 68.63) |
| Week 9: TIS >= 40 Points | 32.3 (21.23 to 45.05) | 26.6 (16.30 to 39.09) |
| Week 9: TIS >= 60 Points | 9.2 (3.46 to 19.02) | 4.7 (0.98 to 13.09) |
| Week 13: TIS >= 20 Points | 73.8 (61.46 to 83.97) | 60.9 (47.93 to 72.90) |
| Week 13: TIS >= 40 Points | 36.9 (25.28 to 49.80) | 31.3 (20.24 to 44.06) |
| Week 13: TIS >= 60 Points | 13.8 (6.53 to 24.66) | 10.9 (4.51 to 21.25) |
| Week 17: TIS >= 20 Points | 75.4 (63.13 to 85.23) | 57.8 (44.82 to 70.06) |
| Week 17: TIS >= 40 Points | 44.6 (32.27 to 57.47) | 34.4 (22.95 to 47.30) |
| Week 17: TIS >= 60 Points | 15.4 (7.63 to 26.48) | 15.6 (7.76 to 26.86) |
| Week 21: TIS >= 20 Points | 73.4 (60.91 to 83.70) | 60.3 (47.20 to 72.43) |
| Week 21: TIS >= 40 Points | 53.1 (40.23 to 65.72) | 33.3 (21.95 to 46.34) |
| Week 21: TIS >= 60 Points | 18.8 (10.08 to 30.46) | 12.7 (5.65 to 23.50) |
| Week 25: TIS >= 20 Points | 64.1 (51.10 to 75.68) | 65.1 (52.03 to 76.66) |
| Week 25: TIS >= 40 Points | 45.3 (32.82 to 58.25) | 39.7 (27.57 to 52.80) |
| Week 25: TIS >= 60 Points | 17.2 (8.90 to 28.68) | 15.9 (7.88 to 27.26) |
Participants were considered and reported in more than one category (TIS \>= 20, \>= 40 and \>= 60 Points).
| percentage of participants | Sequence A: IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 |
|---|---|---|
| Week 25: TIS >= 20 Points | 80.0 (67.03 to 89.57) | 77.8 (64.40 to 87.96) |
| Week 25: TIS >= 40 Points | 56.4 (42.32 to 69.70) | 48.1 (34.34 to 62.16) |
| Week 25: TIS >= 60 Points | 20.0 (10.43 to 32.97) | 18.5 (9.25 to 31.43) |
| Week 29: TIS >= 20 Points | 87.0 (75.10 to 94.63) | 84.9 (72.41 to 93.25) |
| Week 29: TIS >= 40 Points | 64.8 (50.62 to 77.32) | 54.7 (40.45 to 68.44) |
| Week 29: TIS >= 60 Points | 31.5 (19.52 to 45.55) | 22.6 (12.28 to 36.21) |
| Week 33: TIS >= 20 Points | 85.2 (72.88 to 93.38) | 90.6 (79.34 to 96.87) |
| Week 33: TIS >= 40 Points | 57.4 (43.21 to 70.77) | 64.2 (49.80 to 76.86) |
| Week 33: TIS >= 60 Points | 22.2 (12.04 to 35.60) | 24.5 (13.76 to 38.28) |
| Week 37: TIS >= 20 Points | 82.7 (69.67 to 91.77) | 88.5 (76.56 to 95.65) |
| Week 37: TIS >= 40 Points | 57.7 (43.20 to 71.27) | 67.3 (52.89 to 79.67) |
| Week 37: TIS >= 60 Points | 28.8 (17.13 to 43.08) | 25.0 (14.03 to 38.95) |
| Week 41: TIS >= 20 Points | 84.3 (71.41 to 92.98) | 84.6 (71.92 to 93.12) |
| Week 41: TIS >= 40 Points | 64.7 (50.07 to 77.57) | 73.1 (58.98 to 84.43) |
| Week 41: TIS >= 60 Points | 37.3 (24.13 to 51.92) | 30.8 (18.72 to 45.10) |
| Week 45: TIS >= 20 Points | 80.0 (66.28 to 89.97) | 84.3 (71.41 to 92.98) |
| Week 45: TIS >= 40 Points | 64.0 (49.19 to 77.08) | 66.7 (52.08 to 79.24) |
| Week 45: TIS >= 60 Points | 40.0 (26.41 to 54.82) | 31.4 (19.11 to 45.89) |
| Week 49: TIS >= 20 Points | 80.0 (66.28 to 89.97) | 70.0 (55.39 to 82.14) |
| Week 49: TIS >= 40 Points | 68.0 (53.30 to 80.48) | 58.0 (43.21 to 71.81) |
| Week 49: TIS >= 60 Points | 36.0 (22.92 to 50.81) | 22.0 (11.53 to 35.96) |
| Week 53: TIS >= 20 Points | 78.0 (64.04 to 88.47) | 72.0 (57.51 to 83.77) |
| Week 53: TIS >= 40 Points | 56.0 (41.25 to 70.01) | 66.0 (51.23 to 78.79) |
| Week 53: TIS >= 60 Points | 30.0 (17.86 to 44.61) | 24.0 (13.06 to 38.17) |
The observation was censored if no improvement was observed before the intake of rescue/increased doses of oral corticosteroids in SP1 or before the end of the period.
| days | IgPro20 | Placebo |
|---|---|---|
| TIS >= 20 Points | 31.0 (28.00 to 56.00) | 32.0 (28.00 to 56.00) |
| TIS >= 40 Points | 112.0 (63.00 to 141.00) | 112.0 (84.00 to 168.00) |
| TIS >= 60 Points | NA (NA to NA) | NA (170.00 to NA) |
The observation was censored if no improvement was observed before the intake of rescue/increased doses of oral corticosteroids in SP1 or before the end of the period.
| days | Sequence A: IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 |
|---|---|---|
| TIS >= 20 Points | 31.0 (28.00 to 56.00) | 32.0 (28.00 to 56.00) |
| TIS >= 40 Points | 112.0 (63.00 to 141.00) | 137.0 (84.00 to 196.00) |
| TIS >= 60 Points | 308.0 (196.00 to NA) | 336.0 (249.00 to NA) |
Individual CSMs included following: Myositis Disease Activity Assessment Tool (MDAAT) Physician global disease activity (PGDA), PGA assessment, MMT-8, health assessment questionnaire-disability index (HAQ-DI), and MDAAT-EGA. Higher values were associated with a better state of health for the MMT-8 (range 0 -150) assessment, while lower values were associated with a better state of health for: MDAAT-PGDA (range 0 -100), PGA (range 0-100), HAQ-DI (range 0-3), MDAAT-EGA (range 0 -100), and CDASI-A (range 0-100).
| score on a scale | IgPro20 | Placebo |
|---|---|---|
| MMT-8: Week 25 | 10.8 ± 16.71 | 15.2 ± 24.02 |
| MDAAT-PGDA: Week 25 | -21.2 ± 19.86 | -21.8 ± 18.64 |
| MDAAT-EGA: Week 25 | -17.4 ± 22.54 | -13.9 ± 17.67 |
| PGA: Week 25 | -13.0 ± 26.52 | -16.8 ± 20.57 |
| HAQ - DI: Week 25 | -0.195 ± 0.4627 | -0.172 ± 0.4801 |
| CDASI-A: Week 25 | -11.5 ± 10.85 | -7.9 ± 8.91 |
Individual CSMs included following: MDAAT-PGDA, PGA assessment, MMT-8, HAQ-DI, and MDAAT extramacular global assessment. Higher values were associated with a better state of health for the MMT-8 (range 0 -150) assessment, while lower values were associated with a better state of health for: MDAAT-PGDA (range 0 -100), PGA (range 0-100), HAQ-DI (range 0-3), MDAAT-EGA (range 0 -100), and CDASI-A (range 0-100).
| score on a scale | Sequence A: IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 |
|---|---|---|
| MMT-8: Week 53 | 7.1 ± 11.32 | 7.9 ± 13.44 |
| MDAAT-PGDA: Week 53 | -8.5 ± 17.13 | -15.5 ± 18.74 |
| MDAAT-EGA: Week 53 | -0.9 ± 12.38 | -11.5 ± 18.21 |
| PGA: Week 53 | -3.3 ± 20.94 | -9.0 ± 23.87 |
| HAQ - DI: Week 53 | -0.106 ± 0.2587 | -0.162 ± 0.4477 |
| CDASI-A: Week 53 | -0.8 ± 7.52 | -5.3 ± 9.70 |
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment Visual Analog Scale (VAS) worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)
| Participants | IgPro20 | Placebo |
|---|---|---|
| At Least Once | 2 | 3 |
| At Least Twice | 0 | 0 |
| More Than Twice | 0 | 0 |
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)
| percentage of participants | IgPro20 | Placebo |
|---|---|---|
| At Least Once | 3.1 | 4.6 |
| At Least Twice | 0 | 0 |
| More Than Twice | 0 | 0 |
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)
| Participants | Sequence A: IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 |
|---|---|---|
| At Least Once | 2 | 1 |
| At Least Twice | 0 | 0 |
| More Than Twice | 0 | 0 |
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.)
| percentage of participants | Sequence A: IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 |
|---|---|---|
| At Least Once | 3.6 | 1.9 |
| At Least Twice | 0 | 0 |
| More Than Twice | 0 | 0 |
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The observation was censored if no DOW was observed before the intake of rescue treatment or before the end of the period.
| days | Sequence A: IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 |
|---|---|---|
| Time to Meeting DOW for the First Time | NA (NA to NA) | NA (NA to NA) |
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The Number of participants meeting DOW and who received rescue steroid treatment are reported here.
| Participants | IgPro20 | Placebo |
|---|---|---|
| Number of Participants Meeting DOW and Receiving Rescue Steroid Treatment | 0 | 2 |
The DOW consists of meeting 1 of the following criteria on 2 consecutive visits at least 2 weeks apart: PGA Assessment VAS worsening \>= 2 cm\* and MMT-8 worsening \>= absolute 10%, or EGA worsening \>= 2 cm on the MDAAT VAS, or Any 3 of 6 CSM worsening by \>= absolute 20%. (\*If baseline PGA VAS is 8 to 10, then any worsening on Physician Global VAS was acceptable as long as MMT-8 criterion was met.) The percentage of participants meeting DOW and who received rescue steroid treatment are reported here.
| percentage of participants | IgPro20 | Placebo |
|---|---|---|
| Percentage of Participants Meeting DOW and Receiving Rescue Steroid Treatment | 0 | 3.1 |
| Participants | IgPro20 | Placebo |
|---|---|---|
| Number of Participants Who Start Oral Corticosteroid Dose Taper | 19 | 19 |
| percentage of participants | IgPro20 | Placebo |
|---|---|---|
| Percentage of Participants Who Start Oral Corticosteroid Dose Taper | 41.3 | 39.6 |
| Participants | Sequence A: IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 |
|---|---|---|
| Week 25: Reduction >= 25% | 16 | 14 |
| Week 25: Reduction >= 50% | 11 | 8 |
| Week 25: Reduction >= 75% | 3 | 3 |
| Week 52: Reduction >= 25% | 19 | 17 |
| Week 52: Reduction >= 50% | 17 | 14 |
| Week 52: Reduction >= 75% | 12 | 9 |
| percentage of participants | Sequence A: IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 |
|---|---|---|
| Week 25: Reduction >= 25% | 40.0 | 35.9 |
| Week 25: Reduction >= 50% | 27.5 | 20.5 |
| Week 25: Reduction >= 75% | 7.5 | 7.7 |
| Week 52: Reduction >= 25% | 47.5 | 43.6 |
| Week 52: Reduction >= 50% | 42.5 | 35.9 |
| Week 52: Reduction >= 75% | 30.0 | 23.1 |
| percentage of participants | IgPro20 | Placebo |
|---|---|---|
| Percentage of Participants Receiving Rescue Corticosteroid Treatment | 1.5 | 9.2 |
| percentage of participants | IgPro20 | Placebo |
|---|---|---|
| Percentage of Participants Whose Rescue Corticosteroid Treatment is Tapered | 0 | 100.0 |
The observation was censored if no Rescue was observed before the last day of the last week with IMP intake or before the end of the period.
| days | IgPro20 | Placebo |
|---|---|---|
| Time to First Intake of Rescue Corticosteroid Treatment | NA (NA to NA) | NA (NA to NA) |
EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.
| Participants | IgPro20 | Placebo |
|---|---|---|
| Week 13: Mobility: At least 1 level improvement | 16 | 15 |
| Week 13: Mobility: At least 2 level improvement | 1 | 0 |
| Week 13: Mobility: More than 2 level improvement | 0 | 0 |
| Week 13: Self-Care: At least 1 level improvement | 15 | 13 |
| Week 13: Self-Care: At least 2 level improvement | 2 | 2 |
| Week 13: Self-Care: More than 2 level improvement | 1 | 0 |
| Week 13: Usual Activities: At least 1 level improvement | 16 | 15 |
| Week 13: Usual Activities: At least 2 level improvement | 1 | 3 |
| Week 13: Usual Activities: More than 2 level improvement | 1 | 0 |
| Week 25: Mobility: At least 1 level improvement | 10 | 14 |
| Week 25: Mobility: At least 2 level improvement | 5 | 3 |
| Week 25: Mobility: More than 2 level improvement | 0 | 0 |
| Week 25: Self-Care: At least 1 level improvement | 9 | 15 |
| Week 25: Self-Care: At least 2 level improvement | 2 | 3 |
| Week 25: Self-Care: More than 2 level improvement | 2 | 0 |
| Week 25: Usual Activities: At least 1 level improvement | 15 | 13 |
| Week 25: Usual Activities: At least 2 level improvement | 2 | 1 |
| Week 25: Usual Activities: More than 2 level improvement | 1 | 0 |
EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.
| percentage of participants | IgPro20 | Placebo |
|---|---|---|
| Week 13: Mobility : At least 1 level improvement | 28.1 | 27.3 |
| Week 13: Mobility : At least 2 level improvement | 1.8 | 0 |
| Week 13: Mobility : More than 2 level improvement | 0 | 0 |
| Week 13: Self-Care : At least 1 level improvement | 26.3 | 23.6 |
| Week 13: Self-Care : At least 2 level improvement | 3.5 | 3.6 |
| Week 13: Self-Care : More than 2 level improvement | 1.8 | 0 |
| Week 13: Usual Activities : At least 1 level improvement | 28.1 | 27.3 |
| Week 13: Usual Activities : At least 2 level improvement | 1.8 | 5.5 |
| Week 13: Usual Activities : More than 2 level improvement | 1.8 | 0 |
| Week 25: Mobility : At least 1 level improvement | 19.2 | 29.2 |
| Week 25: Mobility : At least 2 level improvement | 9.6 | 6.3 |
| Week 25: Mobility : More than 2 level improvement | 0 | 0 |
| Week 25: Self-Care : At least 1 level improvement | 3.8 | 31.3 |
| Week 25: Self-Care : At least 2 level improvement | 1.9 | 6.3 |
| Week 25: Self-Care : More than 2 level improvement | 1.9 | 0 |
| Week 25: Usual Activities : At least 1 level improvement | 15.8 | 29.3 |
| Week 25: Usual Activities : At least 2 level improvement | 5.3 | 5.2 |
| Week 25: Usual Activities : More than 2 level improvement | 3.5 | 0 |
EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having no reduction, at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.
| Participants | Sequence A: IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 |
|---|---|---|
| Week 41: Mobility: No Reduction | 29 | 28 |
| Week 41: Mobility: At least 1 level improvement | 10 | 8 |
| Week 41: Mobility: At least 2 level improvement | 1 | 0 |
| Week 41: Mobility: More than 2 level improvement | 0 | 1 |
| Week 41: Self-Care: No Reduction | 32 | 31 |
| Week 41: Self-Care: At least 1 level improvement | 5 | 9 |
| Week 41: Self-Care: At least 2 level improvement | 3 | 1 |
| Week 41: Self-Care: More than 2 level improvement | 0 | 0 |
| Week 41: Usual Activities: No Reduction | 23 | 31 |
| Week 41: Usual Activities: At least 1 level improvement | 13 | 10 |
| Week 41: Usual Activities: At least 2 level improvement | 1 | 1 |
| Week 41: Usual Activities: More than 2 level improvement | 1 | 0 |
| Week 53: Mobility: No Reduction | 24 | 25 |
| Week 53: Mobility: At least 1 level improvement | 8 | 7 |
| Week 53: Mobility: At least 2 level improvement | 2 | 0 |
| Week 53: Mobility: More than 2 level improvement | 0 | 1 |
| Week 53: Self-Care: No Reduction | 33 | 23 |
| Week 53: Self-Care: At least 1 level improvement | 2 | 11 |
| Week 53: Self-Care: At least 2 level improvement | 2 | 1 |
| Week 53: Self-Care: More than 2 level improvement | 0 | 0 |
| Week 53: Usual Activities: No Reduction | 21 | 22 |
| Week 53: Usual Activities: At least 1 level improvement | 10 | 10 |
| Week 53: Usual Activities: At least 2 level improvement | 3 | 2 |
| Week 53: Usual Activities: More than 2 level improvement | 0 | 0 |
EQ-5D-5L was assessed across 5 levels, with participants selecting the option that best described their health on that day, ranging from "no problems" to "unable to" walk, wash/dress, or perform usual activities. Out of total participants of each arm, only participants having no reduction, at least 1 Level, 2 Levels, and more than 2 Levels of improvement from baseline in Mobility, Self-care, and Usual Activities Domains of EQ-5D-5L are reported in this outcome measure.
| percentage of participants | Sequence A: IgPro20 / IgPro20 | Sequence B: Placebo / IgPro20 |
|---|---|---|
| Week 41: Mobility: No Reduction | 61.7 | 62.2 |
| Week 41: Mobility: At least 1 level improvement | 21.3 | 17.8 |
| Week 41: Mobility: At least 2 level improvement | 2.1 | 2.2 |
| Week 41: Mobility: More than 2 level improvement | 0 | 0 |
| Week 41: Self-Care: No Reduction | 68.1 | 20.0 |
| Week 41: Self-Care: At least 1 level improvement | 0.6 | 20.0 |
| Week 41: Self-Care: At least 2 level improvement | 6.4 | 2.2 |
| Week 41: Self-Care: More than 2 level improvement | 0 | 0 |
| Week 41: Usual Activities: No Reduction | 48.9 | 68.9 |
| Week 41: Usual Activities: At least 1 level improvement | 27.7 | 22.2 |
| Week 41: Usual Activities: At least 2 level improvement | 2.1 | 2.2 |
| Week 41: Usual Activities: More than 2 level improvement | 2.1 | 0 |
| Week 53: Mobility: No Reduction | 60.0 | 67.6 |
| Week 53: Mobility: At least 1 level improvement | 20.0 | 18.9 |
| Week 53: Mobility: At least 2 level improvement | 5.0 | 0 |
| Week 53: Mobility: More than 2 level improvement | 0 | 2.7 |
| Week 53: Self-Care: No Reduction | 82.5 | 62.2 |
| Week 53: Self-Care: At least 1 level improvement | 5.0 | 29.7 |
| Week 53: Self-Care: At least 2 level improvement | 5.0 | 2.7 |
| Week 53: Self-Care: More than 2 level improvement | 0 | 0 |
| Week 53: Usual Activities: No Reduction | 52.5 | 59.5 |
| Week 53: Usual Activities: At least 1 level improvement | 25.0 | 27.0 |
| Week 53: Usual Activities: At least 2 level improvement | 7.5 | 5.4 |
| Week 53: Usual Activities: More than 2 level improvement | 0 | 0 |
| percentage of participants | Period 1 Sequence A: IgPro20 | Period 1 Sequence B: Placebo | Period 2 Sequence A: IgPro20 / IgPro20 | Period 2 Sequence B: Placebo / IgPro20 | Period 3 Sequence A: IgPro20/ IgPro20 / IgPro20 | Period 3 Sequence B: Placebo / IgPro20 / IgPro20 |
|---|---|---|---|---|---|---|
| TEAEs | 82.1 | 67.2 | 69.6 | 74.5 | 75.0 | 76.5 |
| Related TEAEs | 52.2 | 25.4 | 17.9 | 43.6 | 13.9 | 20.6 |
| Serious TEAEs | 4.5 | 7.5 | 3.6 | 5.5 | 13.9 | 20.6 |
| TEAEs per year | Period 1 Sequence A: IgPro20 | Period 1 Sequence B: Placebo | Period 2 Sequence A: IgPro20 / IgPro20 | Period 2 Sequence B: Placebo / IgPro20 | Period 3 Sequence A: IgPro20/ IgPro20 / IgPro20 | Period 3 Sequence B: Placebo / IgPro20 / IgPro20 |
|---|---|---|---|---|---|---|
| TEAEs | 11.725 | 5.359 | 4.922 | 6.718 | 3.165 | 3.644 |
| Related TEAEs | 6.327 | 0.936 | 1.348 | 2.166 | 0.195 | 0.240 |
| Serious TEAEs | 0.214 | 0.226 | 0.067 | 0.110 | 0.137 | 0.288 |
| TEAEs per year | Period 1 Sequence A: IgPro20 | Period 1 Sequence B: Placebo | Period 2 Sequence A: IgPro20 / IgPro20 | Period 2 Sequence B: Placebo / IgPro20 | Period 3 Sequence A: IgPro20/ IgPro20 / IgPro20 | Period 3 Sequence B: Placebo / IgPro20 / IgPro20 |
|---|---|---|---|---|---|---|
| Mild | 9.151 | 4.035 | 4.011 | 4.332 | 2.442 | 2.157 |
| Moderate | 2.145 | 1.162 | 0.843 | 2.239 | 0.606 | 1.390 |
| Severe | 0.393 | 0.161 | 0.067 | 0.110 | 0.117 | 0.096 |
Collected over Up to 5 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Period 1 Sequence A: IgPro20 | 1/67 (1.5%) | 3/67 (4.5%) | 41/67 (61.2%) |
| Period 1 Sequence B: Placebo | 1/67 (1.5%) | 5/67 (7.5%) | 33/67 (49.3%) |
| Period 2 Sequence A: IgPro20 / IgPro20 | 1/56 (1.8%) | 2/56 (3.6%) | 25/56 (44.6%) |
| Period 2 Sequence B: Placebo / IgPro20 | 0/55 (0%) | 3/55 (5.5%) | 33/55 (60%) |
| Period 3 Sequence A: IgPro20/ IgPro20 / IgPro20 | 0/36 (0%) | 5/36 (13.9%) | 21/36 (58.3%) |
| Period 3 Sequence B: Placebo / IgPro20 / IgPro20 | 1/34 (2.9%) | 7/34 (20.6%) | 17/34 (50%) |
| Event | Period 1 Sequence A: IgPro20 | Period 1 Sequence B: Placebo | Period 2 Sequence A: IgPro20 / IgPro20 | Period 2 Sequence B: Placebo / IgPro20 | Period 3 Sequence A: IgPro20/ IgPro20 / IgPro20 | Period 3 Sequence B: Placebo / IgPro20 / IgPro20 |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 1/67 | 0/67 | 0/56 | 0/55 | 0/36 | 2/34 |
| COVID-19 pneumoniaInfections and infestations | 1/67 | 2/67 | 0/56 | 0/55 | 0/36 | 0/34 |
| PneumoniaInfections and infestations | 1/67 | 0/67 | 0/56 | 0/55 | 0/36 | 1/34 |
| Urinary tract infectionInfections and infestations | 1/67 | 0/67 | 0/56 | 0/55 | 0/36 | 1/34 |
| CystitisInfections and infestations | 0/67 | 0/67 | 0/56 | 0/55 | 0/36 | 1/34 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/67 | 0/67 | 0/56 | 0/55 | 0/36 | 1/34 |
| DermatomyositisMusculoskeletal and connective tissue disorders | 0/67 | 0/67 | 0/56 | 0/55 | 0/36 | 1/34 |
| Sudden deathGeneral disorders | 0/67 | 0/67 | 0/56 | 0/55 | 0/36 | 1/34 |
| Mueller's mixed tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/67 | 0/67 | 0/56 | 0/55 | 0/36 | 1/34 |
| SyncopeNervous system disorders | 0/67 | 0/67 | 0/56 | 0/55 | 0/36 | 1/34 |
| Event | Period 1 Sequence A: IgPro20 | Period 1 Sequence B: Placebo | Period 2 Sequence A: IgPro20 / IgPro20 | Period 2 Sequence B: Placebo / IgPro20 | Period 3 Sequence A: IgPro20/ IgPro20 / IgPro20 | Period 3 Sequence B: Placebo / IgPro20 / IgPro20 |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 5/67 | 4/67 | 6/56 | 4/55 | 13/36 | 8/34 |
| NasopharyngitisInfections and infestations | 2/67 | 3/67 | 2/56 | 5/55 | 8/36 | 6/34 |
| Infusion site erythemaGeneral disorders | 12/67 | 4/67 | 1/56 | 10/55 | 0/36 | 0/34 |
| HeadacheNervous system disorders | 12/67 | 3/67 | 3/56 | 3/55 | 4/36 | 0/34 |
| Urinary tract infectionInfections and infestations | 1/67 | 2/67 | 0/56 | 2/55 | 2/36 | 4/34 |
| Infusion site painGeneral disorders | 4/67 | 1/67 | 1/56 | 5/55 | 1/36 | 0/34 |
| NauseaGastrointestinal disorders | 6/67 | 4/67 | 0/56 | 1/55 | 2/36 | 0/34 |
| Infusion site swellingGeneral disorders | 6/67 | 1/67 | 0/56 | 3/55 | 0/36 | 0/34 |
| DiarrhoeaGastrointestinal disorders | 3/67 | 4/67 | 5/56 | 3/55 | 2/36 | 3/34 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 0/67 | 0/67 | 0/56 | 0/55 | 1/36 | 3/34 |
Analysis was performed on the safety (SAF) analysis set. The SAF analysis set comprised all participants who were randomized and received any amount of randomized investigational medicinal product (IMP) and were based on the actual treatment sequence received. Here, baseline characteristics are reported for Period 1, as participants from this cohort were selected to proceed to Periods 2 and 3.
| Age, Continuous(years) | IgPro20 | Placebo | Total |
|---|---|---|---|
| Mean | 51.5 ± 15.86 | 49.1 ± 14.02 | 50.3 ± 14.96 |
| Sex: Female, Male(Participants) | IgPro20 | Placebo | Total |
|---|---|---|---|
| Female | 47 | 51 | 98 |
| Male | 20 | 16 | 36 |
| Ethnicity (NIH/OMB)(Participants) | IgPro20 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 15 | 29 |
| Not Hispanic or Latino | 51 | 49 | 100 |
| Unknown or Not Reported | 2 | 3 | 5 |
| Race/Ethnicity, Customized(Participants) | IgPro20 | Placebo | Total |
|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 |
| Race — Asian | 10 | 10 | 20 |
| Race — Black or African American | 3 | 1 | 4 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Race — White | 48 | 50 | 98 |
| Race — Other | 6 | 6 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com. Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD. If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.
Supporting information: Study protocol, Statistical analysis plan
Time frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
Access criteria: Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee. An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee. The requesting party must execute an appropriate data sharing agreement before IPD will be made available.
Ran from Oct 2019 to primary completion in Dec 2024, 61 months.
Results were first posted in Dec 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous